Antibody-Drug Conjugates (ADC): Market Overview

Antibody-Drug Conjugates (ADC): Market Overview


Summary

Clients will gain insight into the competitive landscape of leading antibody-drug conjugates (ADC) in oncology including SWOT analysis for key marketed and pipeline drugs, clinical benchmark comparisons, key clinical trial analysis, analyst consensus forecasts, and commentary on current and future players. The report also includes outlook from four key opinion leaders in the US and analyzes key opportunities and challenges in the space. Additionally, the report includes commentary on the latest trends in ADC development including payload and linker analysis.

An ADC drug consists of monoclonal antibodies conjugated to a payload via a linker, for the precise targeting of antigen-positive cancer cells.

ADCs are developed to target protein receptors with high expression such as HER2, TROP-2, CD22, and others.

There are two cytotoxic payload types predominantly used in ADCs: microtubule inhibitors (MMAE, DM1/DM4), and the more potent DNA-damaging payloads such as topoisomerase I inhibitors (DXd, SN38).

Linkers maintain the stability of the ADC and may induce a ‘bystander effect’ if the payload is released adjacent to the tumor cell.

The global ADC market grew from $50 million in 2011 to $9.2 billion by 2023. GlobalData anticipates the market to exceed $40 billion by 2029.

The rapid growth seen is due to several blockbuster ADCs: Daiichi Sankyo’s Enhertu, Roche’s Kadcyla, Astellas Pharma & Pfizer’s Padcev, and Gilead’s Trodelvy, as well as the commercial success of other ADCs.

Daiichi’s deruxtecan payload technology has led to HER2-targeting Enhertu, the highest-grossing ADC approved for multiple indications. Enhertu generated $3.4 billion in 2023 and is projected to reach $14 billion by 2029. Additionally, the company has several pipeline agents expected to have marked commercial success, notably TROP-2-targeting DS-1062 for metastatic breast and non-small cell lung cancer (NSCLC).

In December 2023, Pfizer completed a $43 billion acquisition of ADC-focused biotech Seagen. Through the buy-out, Pfizer gained the rights to Padcev and a pipeline of early-stage ADCs.

Scope

Clinical trial analysis includes all countries

5 KOLs interviewed

Reasons to Buy

OBTAIN A COMPETITIVE ASSESMENT FOR ANTIBODY DRUG CONJUGATES IN ONCOLOGY ACROSS MULTIPLE REGIONS

Our modality-specific reports answer questions such as -
  • What is the future global market value of ADCs in Oncology?
  • Which cancer types are more likely to receive these therapies?
  • What are the clinical benchmarks for currently approved ADCs?
  • What are the emergent linkers and paylods for ADCs?
  • What is the key opinion leaders’ outlook for the products?
  • What are key opportunities and challenges in the area?


  • Executive Summary
  • ADCs Overview
    • What Are Antibody-Drug Conjugates?
    • History of Antibody-Drug Conjugate Development
    • KOL Perspective on ADCs
  • Industry Trends
    • Industry Trends: Key Marketed ADCs
    • Industry Trends: Hematological Cancers Emerging Targets for ADCs
    • Industry Trends: Emerging Targets for ADCs
    • Industry Trends: Current Payloads
    • Industry Trends: Emerging Payloads
    • Industry Trends: Linkers
    • Clinical Benchmarks: HER2+ Breast Cancer
    • Clinical Benchmarks: Bladder Cancer
    • Clinical Benchmarks: Metastatic Ovarian Cancer
    • Clinical Benchmarks: Diffuse Large B-Cell Lymphoma
  • Marketed Products
    • Global ADC Marketed Landscape
    • Product Profile: Daiichi Sankyo's Enhertu (trastuzumab deruxtecan)
    • Product Profile: Roche's Kadcyla (trastuzumab emtansine) &RemeGen/Pfizer's Aidixi (disitamab vedotin)
    • KOL Perspective on Marketed HER2-Targeted ADCs
    • Product Profile: Gilead's Trodelvy (sacituzumab govitecan)
    • KOL Perspective on Trodelvy (sacituzumab govitecan)
    • Product Profile: Genmab's Tivdak (tisotumab vedotin)
    • Product Profile: Rakuten Medical's Akalux (cetuximab sarotalocan)
    • Product Profile: Astellas Pharma & Pfizer's Padcev (enfortumab vedotin)
    • Product Profile: Immunogen's Elahere (mirvetuximab soravtansine)
    • KOL Perspective on Elahere and Padcev
    • Product Profile: Pfizer's Mylotarg (gemtuzumab ozogamicin)
    • Product Profile: ADC Therapeutics's Zynlonta (loncastuximab tesirine)
    • Product Profile: Pfizer's Besponsa (inotuzumab ozogamicin)
    • Product Profile: Roche's Polivy (polatuzumab vedotin)
    • Product Profile: Pfizer's Adcetris (brentuximab vedotin)
    • KOL Perspective on Marketed ADCs (Hematology)
  • Pipeline Products
    • ADC Pipeline Candidates - Global
    • Product Profile: Ambrx Biopharma's ARX788 (anvatabart opadotin)
    • Product Profile: Fosun Pharmaceuticals's FS-1502 & KLUS Pharma's A-166 (trastuzumab botidotin)
    • Product Profile: Lepu BioPharma's MRG-002 & Hengrui Medicine's SHR-A1811 (trastuzumab rezetecan)
    • Product Profile: Bispecific ADC Alphamab Oncology's JSKN003
    • Product Profile: Daiichi Sankyo & AstraZeneca's DS-1062 (datopotamab deruxtecan)
    • KOL Perspective on Datopotamab Deruxtecan
    • Product Profile: KLUS Pharma's SKB264/Merck's MK2870 (sacituzumab tirumotecan)
    • Product Profile: Daiichi Sankyo's U-31402 (patritumab deruxtecan)
    • Product Profile: Merck's MK-2140 (zilovertamab vedotin)
    • Product Profile: Lepu Biopharma's MRG-003
    • Product Profile: AbbVie's ABBV-399 (telisotuzumab vedotin)
    • Product Profile: Sutro Biopharma's STRO-002 (luveltamab tazevibulin)
    • Product Profile: ImmunoGen's IMGN632 (pivekimab sunirine)
    • Product Profile: GSK's Blenrep (belantamab mafodotin)
    • Product Profile: Eisai/BMS's MORAb-202 (farletuzumab ecteribulin)
    • KOL Perspective on Pipeline
  • Opportunities and Challenges
  • Companies
    • Current Major Player: Daiichi Sankyo
    • Current Major Player: Pfizer
    • Current Major Player: Roche
    • Current Major Player: AstraZeneca
    • Future Major Player: Hengrui Medicine
    • Future Major Player: AbbVie
    • Future Major Player: Kelun Biotech
    • Future Major Player: Lepu Biopharma
  • Market Outlook and Deals
    • ADC Global Market
    • Sales for ADCs in the Pipeline
    • Top 20 Major Deals and Acquisitions between 2021 and 2024 in ADCs
  • Appendix
    • Bibliography
    • Primary Research

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings